Independent verification support
Japan Regenerative MedicineRegistration and Compliance
If you’re thinking about paying for stem-cell or regenerative medicine treatment in Japan, here’s what you’ll want to nail down first: the exact treatment plan, which regulatory route it took, the consent documents, what the clinical evidence actually says, the real cost, and what follow-up you’ll need.
What we do: review the information you’ve been given, coordinate your appointments, and handle medical translation. Diagnosis, eligibility, and any treatment decision stay with your doctor.
Four things to verify
Four questions to settle before treatment
The exact treatment name matters—a lot. Two plans that sound almost the same can have different registration status, different evidence, different cell sources, different administration methods, and different follow-up requirements.
Two different paths
Registration is not the same as product approval
Japan regulates regenerative medicine through separate legal routes. The Act on the Safety of Regenerative Medicine covers cell-based medical practice and research, while the PMD Act regulates the commercialization of regenerative medical products. PMDA
Regenerative medicine techniques are classified by risk, reviewed through the applicable certified committee process, and treatment plans are filed under the statutory framework.
Regenerative medical products are reviewed through the product-approval system for quality, safety and efficacy before marketing authorization.
PMDA reported 26 regenerative medical products currently approved under the PMD Act as of 20 May 2026. That figure should not be used to imply that every privately offered stem-cell treatment is an approved product. PMDA 2026
Got documents but still no clear answer?
Share the exact treatment name and whatever written material you’ve already received. We’ll help make sense of it.
What’s in the public record
Details that should match your documents
MHLW publishes treatment-plan information specifically to help patients make informed choices. You’ll find treatment names, provider details, which certified committee reviewed it, explanation and consent documents, and regulatory orders when they apply. MHLW
The wording should match the treatment being proposed, not only a broad label such as stem-cell therapy.
Japan classifies regenerative medicine techniques into Class I, Class II and Class III according to risk. MHLW FAQ
Check the committee identified in the public record and in the documents provided for the proposed treatment.
Read the patient explanation and consent materials before agreeing to treatment or making a non-refundable payment.
Where applicable, public records can show orders issued under the relevant provisions of the Safety Act.
Use current official sources. The amended Safety Act framework took effect on 31 May 2025 and MHLW continues to publish regulatory updates. MHLW law updates
Different diagnosis, different evidence
Registration does not tell you how much benefit to expect
What makes the clinical question specific: your diagnosis, disease stage, cell source, dose, route, what you’re comparing against, and how long they followed people up.
Review pain and function scores, mobility, imaging findings, durability and whether surgery was avoided or only delayed.
Review neurologic scales, motor and sensory function, injury level, injury duration and the rehabilitation program used alongside treatment.
Review HbA1c, insulin requirement, hypoglycemia, disease type, complications and whether outcomes are sustained beyond short follow-up.
Review functional disability, exercise capacity, major cardiovascular events, mortality when relevant, and the effect of rehabilitation or standard therapy.
Review ovarian markers, ovulation, pregnancy and live-birth outcomes where available rather than relying on hormone changes alone.
Review organ-function measures, hospitalization, progression, transplant-related outcomes and clinically meaningful safety data.
A case report or individual patient story can describe clinical experience, but it cannot establish the benefit you should expect. Controlled evidence and disease-specific follow-up carry more decision value.
Separating fact from theory
Effectiveness without promises
Good evidence review does one thing well: it separates what’s actually been measured from what someone’s proposed might happen in theory.
Prioritize guidelines, systematic reviews and controlled trials, then use prospective studies and case series as supporting context.
Check whether the study used the same diagnosis, disease stage, cell source, preparation, dose and administration route.
Focus on function, symptoms, complications, hospitalization, survival when relevant, quality of life and durability.
You can’t decide if you’re a candidate from a website or a registry entry. Medical records, current standard treatment, contraindications and individual risk all have to be reviewed by the physician treating you.
Survival and Recovery
There is no valid universal survival rate
Survival only makes sense as an endpoint for certain diseases. For most chronic or musculoskeletal conditions, what you’d actually want to track is pain, function, independence, organ performance, complications, and quality of life.
Use disease-specific mortality or survival outcomes only when comparable evidence exists. Do not substitute laboratory changes for survival evidence.
Compare baseline status, rehabilitation intensity, follow-up duration and the proportion of patients achieving a clinically meaningful change.
Ask whether benefit persisted, whether repeat treatment was required, what adverse events occurred and what standard care continued during follow-up.
Do not delay established treatment, emergency care, rehabilitation or disease monitoring while considering regenerative medicine.
Not sure what the numbers actually mean?
Send the report, quote or consent document you are comparing.
What you’re really paying for
Compare the whole care pathway, not one fee
There’s no single price tag for regenerative medicine in Japan. To make a meaningful comparison, you need to know the exact treatment, cell source, number of sessions, how they process the cells, and what the follow-up plan looks like.
Consultation, blood work, imaging and any disease-specific baseline testing.
Collection method, processing, culture where applicable, storage and quality checks.
Injection or infusion procedure, medications, anesthesia or procedure-related support where applicable.
Initial plan, possible repeat treatment and the conditions under which additional sessions are proposed.
Monitoring, repeat testing, rehabilitation and management of complications or adverse events.
Translation or coordination support, travel, accommodation and any return visit requirements.
A written breakdown beats a package price every time. If something’s not in the quote, you’ll want to know before you pay.
Prepare Your Verification Request
Send enough information to check what you were actually offered
Clear documents make everything easier—you’ll spot the registration status, see where the evidence is thin, flag the cost questions, and know exactly what to confirm with the doctor.
Include the most specific diagnosis available and when it was confirmed.
Include major imaging, laboratory results, pathology where relevant and recent specialist summaries.
Include the written treatment name, cell source, route, number of sessions and any dose information provided.
Include what is covered, what is excluded, payment terms and any repeat-treatment pricing.
Send the version you were asked to review so it can be compared with official public information where available.
State your preferred language and planned timing if appointment coordination or medical translation is needed.
Questions Before Consent
Answers worth getting in writing
When it’s in writing, you can separate verified regulatory facts from what someone’s assuming, and compare what’s being proposed against the evidence that actually matters for your diagnosis.
Is an MHLW-listed treatment plan the same as PMDA product approval?
No. They are different regulatory concepts. A treatment plan filed under the Safety Act should not be presented as if it automatically means that the therapy is a PMDA-approved regenerative medical product.
Does registration prove that the treatment will work for my disease?
No. Registration and effectiveness answer different questions. Clinical benefit must be judged from evidence that matches your diagnosis, stage, treatment method and meaningful outcomes.
How can I check the exact treatment plan?
Use the MHLW public treatment-plan database and compare the exact treatment name, provider information, certified committee, explanation and consent documents, and any listed regulatory orders.
Can a general survival rate be given for stem-cell therapy?
No. Survival must be tied to a specific disease and evidence set. For conditions where survival is not the main clinical endpoint, function, symptoms, complications, organ performance, quality of life and durability are usually more informative.
How should I compare treatment cost?
Compare the full pathway: assessment, testing, cell collection and processing, administration, number of sessions, medications, follow-up, rehabilitation, translation or coordination, travel and any costs that may arise if additional treatment is proposed.
What should not be delayed while I consider regenerative medicine?
Do not delay established medical treatment, emergency care, disease monitoring or rehabilitation without discussing the consequences with the physician responsible for your care.
Official Sources
Verify with current Japanese regulatory information
We start with official sources because treatment-plan status and regulatory information don’t stay the same forever.
Before You Commit
Send the exact documents and get a clearer picture
We’ll organize what you need: a registration check, the regulatory distinctions, diagnosis-specific evidence questions, a cost breakdown, and the follow-up points worth clarifying before you decide.
We organize information, verify against official sources, coordinate appointments, and handle medical translation. We don’t diagnose disease, prescribe treatment, provide treatment, guarantee results, or replace your doctor’s advice. A treatment being registered doesn’t prove it works for you.